(Q36639857)

15 August 2017

1 reference

title

Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists-an opportunity to improve outcomes (English)

1 reference

15 August 2017

0 references

Edward C Keystone

1

1 reference

15 August 2017

publication date

1 November 2006

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

594-601

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

15 August 2017

1 reference

7 January 2021

Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Elucidation of the relationship between synovitis and bone damage: A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Imaging in early rheumatoid arthritis: roles of magnetic resonance imaging, ultrasonography, conventional radiography and computed tomography

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Treatment of early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Infliximab in active early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Infliximab treatment maintains employability in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0340

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0340

1 reference

15 August 2017

1 reference